Over the past five years, we have seen remarkable growth and clinical results in an area of medicine known as advanced therapy medicinal products (ATMPs), which comprise gene therapies, somatic cell therapies, and tissue engineered products. These treatments offer the potential to address significant and growing unmet healthcare needs. Ian Hollingsworth of Cell and Gene Therapy Catapult explains how they offer the promise of treating and altering the course of diseases which cannot be addressed adequately by existing pharmaceuticals, offering a lifeline to some patients who have failed all other treatment options.

[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2020/07/Increasing-Patient-Access-to-Advanced-Therapies.pdf”]